P409: NPM1 MUTATED SAMPLES ARE ESPECIALLY VULNERABLE WHEN TARGETING RAC1 IN PATIENT-DERIVED AML CELLS IN VITRO

• A. Hemsing,
• K. P. Rye,
• K. J. Hatfield,
• H. Reikvam

Affiliations

A. Hemsing

1 Department of Medicine, Haukeland University Hospital

K. P. Rye

2 Department of Clinical Science, University of Bergen

K. J. Hatfield

3 Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway

H. Reikvam

1 Department of Medicine, Haukeland University Hospital